Détente: A Practical Understanding of P values and Bayesian Posterior Probabilities
Null hypothesis significance testing (NHST) with its benchmark P value < 0.05 has long been a stalwart of scientific reporting and such statistically significant findings have been used to imply scientifically or clinically significant findings. Challenges to this approach have arisen over the pa...
Gespeichert in:
| Veröffentlicht in: | Clinical pharmacology and therapeutics Jg. 109; H. 6; S. 1489 - 1498 |
|---|---|
| 1. Verfasser: | |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
01.06.2021
|
| ISSN: | 0009-9236, 1532-6535, 1532-6535 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Null hypothesis significance testing (NHST) with its benchmark P value < 0.05 has long been a stalwart of scientific reporting and such statistically significant findings have been used to imply scientifically or clinically significant findings. Challenges to this approach have arisen over the past 6 decades, but they have largely been unheeded. There is a growing movement for using Bayesian statistical inference to quantify the probability that a scientific finding is credible. There have been differences of opinion between the frequentist (i.e., NHST) and Bayesian schools of inference, and warnings about the use or misuse of P values have come from both schools of thought spanning many decades. Controversies in this arena have been heightened by the American Statistical Association statement on P values and the further denouncement of the term “statistical significance” by others. My experience has been that many scientists, including many statisticians, do not have a sound conceptual grasp of the fundamental differences in these approaches, thereby creating even greater confusion and acrimony. If we let A represent the observed data, and B represent the hypothesis of interest, then the fundamental distinction between these two approaches can be described as the frequentist approach using the conditional probability pr(A | B) (i.e., the P value), and the Bayesian approach using pr(B | A) (the posterior probability). This paper will further explain the fundamental differences in NHST and Bayesian approaches and demonstrate how they can co‐exist harmoniously to guide clinical trial design and inference. |
|---|---|
| AbstractList | Null hypothesis significance testing (NHST) with its benchmark P value < 0.05 has long been a stalwart of scientific reporting and such statistically significant findings have been used to imply scientifically or clinically significant findings. Challenges to this approach have arisen over the past 6 decades, but they have largely been unheeded. There is a growing movement for using Bayesian statistical inference to quantify the probability that a scientific finding is credible. There have been differences of opinion between the frequentist (i.e., NHST) and Bayesian schools of inference, and warnings about the use or misuse of P values have come from both schools of thought spanning many decades. Controversies in this arena have been heightened by the American Statistical Association statement on P values and the further denouncement of the term "statistical significance" by others. My experience has been that many scientists, including many statisticians, do not have a sound conceptual grasp of the fundamental differences in these approaches, thereby creating even greater confusion and acrimony. If we let A represent the observed data, and B represent the hypothesis of interest, then the fundamental distinction between these two approaches can be described as the frequentist approach using the conditional probability pr(A | B) (i.e., the P value), and the Bayesian approach using pr(B | A) (the posterior probability). This paper will further explain the fundamental differences in NHST and Bayesian approaches and demonstrate how they can co-exist harmoniously to guide clinical trial design and inference.Null hypothesis significance testing (NHST) with its benchmark P value < 0.05 has long been a stalwart of scientific reporting and such statistically significant findings have been used to imply scientifically or clinically significant findings. Challenges to this approach have arisen over the past 6 decades, but they have largely been unheeded. There is a growing movement for using Bayesian statistical inference to quantify the probability that a scientific finding is credible. There have been differences of opinion between the frequentist (i.e., NHST) and Bayesian schools of inference, and warnings about the use or misuse of P values have come from both schools of thought spanning many decades. Controversies in this arena have been heightened by the American Statistical Association statement on P values and the further denouncement of the term "statistical significance" by others. My experience has been that many scientists, including many statisticians, do not have a sound conceptual grasp of the fundamental differences in these approaches, thereby creating even greater confusion and acrimony. If we let A represent the observed data, and B represent the hypothesis of interest, then the fundamental distinction between these two approaches can be described as the frequentist approach using the conditional probability pr(A | B) (i.e., the P value), and the Bayesian approach using pr(B | A) (the posterior probability). This paper will further explain the fundamental differences in NHST and Bayesian approaches and demonstrate how they can co-exist harmoniously to guide clinical trial design and inference. Null hypothesis significance testing (NHST) with its benchmark P value < 0.05 has long been a stalwart of scientific reporting and such statistically significant findings have been used to imply scientifically or clinically significant findings. Challenges to this approach have arisen over the past 6 decades, but they have largely been unheeded. There is a growing movement for using Bayesian statistical inference to quantify the probability that a scientific finding is credible. There have been differences of opinion between the frequentist (i.e., NHST) and Bayesian schools of inference, and warnings about the use or misuse of P values have come from both schools of thought spanning many decades. Controversies in this arena have been heightened by the American Statistical Association statement on P values and the further denouncement of the term “statistical significance” by others. My experience has been that many scientists, including many statisticians, do not have a sound conceptual grasp of the fundamental differences in these approaches, thereby creating even greater confusion and acrimony. If we let A represent the observed data, and B represent the hypothesis of interest, then the fundamental distinction between these two approaches can be described as the frequentist approach using the conditional probability pr(A | B) (i.e., the P value), and the Bayesian approach using pr(B | A) (the posterior probability). This paper will further explain the fundamental differences in NHST and Bayesian approaches and demonstrate how they can co‐exist harmoniously to guide clinical trial design and inference. |
| Author | Ruberg, Stephen J. |
| Author_xml | – sequence: 1 givenname: Stephen J. surname: Ruberg fullname: Ruberg, Stephen J. email: analytixthinking@gmail.com organization: Analytix Thinking, LLC |
| BookMark | eNotkM1Kw0AUhQepYFsFH2GWblLnNz_uaq0_UDCLuB5ukjsykk5qZqr0kXwOX8yUujqcyzmHyzcjE997JOSaswVnTNw2u7gQjKkzMuVaiiTVUk_IlDFWJIWQ6QWZhfAxWlXk-ZRUD78_EX3EO7qk5QBNdA109M23OIQIvnX-nfaWlvQLuj0GOp7oPRwwOPC07EPEwfXDWO1rqF3nosNwSc4tdAGv_nVOqsd1tXpONq9PL6vlJmkkEyrhaBtteW610qkSKFrM2lQXIIsma-sc0HIExmVqrahzXkhVK8GAyyzNBcg5uTnN7ob-c_wtmq0LDXYdeOz3wQglmUzzTBdjNDlFv12HB7Mb3BaGg-HMHKGZEZo5QjOrsjqq_AOU-mM6 |
| CitedBy_id | crossref_primary_10_3389_fimmu_2025_1520615 crossref_primary_10_1186_s13023_022_02342_5 crossref_primary_10_1097_PSY_0000000000001129 crossref_primary_10_3389_fpls_2025_1459126 crossref_primary_10_3389_fimmu_2023_1269650 crossref_primary_10_37349_edd_2025_100578 crossref_primary_10_1186_s12916_025_04166_z crossref_primary_10_1016_j_rmal_2025_100256 crossref_primary_10_1016_j_fcr_2024_109345 crossref_primary_10_1038_s41573_023_00638_0 |
| ContentType | Journal Article |
| Copyright | 2020 The Authors. published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. 2020 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. |
| Copyright_xml | – notice: 2020 The Authors. published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. – notice: 2020 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. |
| DBID | 24P 7X8 |
| DOI | 10.1002/cpt.2004 |
| DatabaseName | Wiley Online Library Open Access MEDLINE - Academic |
| DatabaseTitle | MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1532-6535 |
| EndPage | 1498 |
| ExternalDocumentID | CPT2004 |
| Genre | article |
| GroupedDBID | --- --K -Q- .55 .GJ 0R~ 1B1 1CY 1OB 1OC 24P 29B 33P 354 36B 39C 3O- 4.4 52O 53G 5GY 5RE 6J9 70F 8F7 AAESR AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AAQOH AAQQT AAWTL AAYCA AAYOK AAZKR ABCUV ABJNI ABLJU ABQWH ACBNA ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACPOU ACRPL ACXQS ACYXJ ADBBV ADBTR ADKYN ADNMO ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AENEX AEQDE AEUYR AFBPY AFFNX AFFPM AHBTC AI. AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMYDB ASPBG AVWKF AZFZN AZVAB BDRZF BFHJK BMXJE BRXPI C45 CAG COF CS3 DCZOG DPXWK DU5 EBS EE. EJD EMOBN F5P GODZA GWYGA HGLYW IH2 IHE J5H L7B LATKE LEEKS LITHE LOXES LSO LUTES LYRES M41 MEWTI N4W N9A NQ- O9- OPC OVD P2P P2W PALCI RIG RIWAO RJQFR RNTTT ROL RPZ SAMSI SEW SJN SUPJJ TEORI TWZ UHS VH1 WBKPD WH7 WOHZO WXSBR WYJ X7M Y6R YCJ YFH YOC YXB ZGI ZXP ZZTAW 7X8 AAMMB AEFGJ AEYWJ AGHNM AGXDD AGYGG AIDQK AIDYY |
| ID | FETCH-LOGICAL-c3024-1efc5f18f545642e2de7d659a39c7db8aef1ea0136ff2b81934b420a137682a3 |
| IEDL.DBID | 24P |
| ISSN | 0009-9236 1532-6535 |
| IngestDate | Thu Oct 02 06:12:05 EDT 2025 Wed Jan 22 16:30:29 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3024-1efc5f18f545642e2de7d659a39c7db8aef1ea0136ff2b81934b420a137682a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcpt.2004 |
| PQID | 2430368759 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_2430368759 wiley_primary_10_1002_cpt_2004_CPT2004 |
| PublicationCentury | 2000 |
| PublicationDate | June 2021 |
| PublicationDateYYYYMMDD | 2021-06-01 |
| PublicationDate_xml | – month: 06 year: 2021 text: June 2021 |
| PublicationDecade | 2020 |
| PublicationTitle | Clinical pharmacology and therapeutics |
| PublicationYear | 2021 |
| References | 2017; 318 1966; 19 2019; 73 2011 1933; 231 2018; 564 2018; 169 2020; 17 2019; 567 1997 1926; 33 1994 2016; 72 2016; 70 1962; 33 2017; 112 1992; 11 2019; 381 2016; 164 2019; 321 2004; 33 2004; 96 1763; 53 2014; 506 1987; 82 2001; 6 1987; 257 2004; 14 2002; 21 2014; 36 1999; 130 2017; 140 1978; 48 2005; 2 2001; 55 1925 2014; 12 1989 2014; 32 |
| References_xml | – year: 2011 – volume: 231 start-page: 289 year: 1933 end-page: 337 article-title: On the problem of the most efficient tests of statistical hypotheses publication-title: Philos. Trans. R Soc. A – volume: 130 start-page: 995 year: 1999 end-page: 1004 article-title: Toward evidence‐based medical statistics. 1: the P value fallacy publication-title: Ann. Intern. Med. – volume: 506 start-page: 150 year: 2014 end-page: 152 article-title: Scientific method: statistical errors publication-title: Nature – volume: 33 start-page: 587 year: 2004 end-page: 606 article-title: Mindless statistics publication-title: J. Socio. Econ. – volume: 55 start-page: 62 year: 2001 end-page: 71 article-title: Calibration of p values for testing precise null hypotheses publication-title: Am. Stat. – volume: 164 start-page: 279 year: 2016 end-page: 296 article-title: Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement publication-title: Ann. Int. Med. – volume: 12 year: 2014 article-title: Distinguishing between exploratory and confirmatory preclinical research will improve translation publication-title: PLoS Biol. – volume: 321 start-page: 2067 year: 2019 end-page: 2068 article-title: The importance of predefined rules and prespecified statistical analyses: do not abandon significance publication-title: JAMA – year: 1989 – volume: 112 start-page: 885 year: 2017 end-page: 895 article-title: Statistical significance and the dichotomization of evidence publication-title: J. Am. Stat. Assoc. – volume: 73 start-page: 319 issue: suppl. 1 year: 2019 end-page: 327 article-title: Inference and decision making for 21st‐century drug development and approval publication-title: Am. Stat. – volume: 33 start-page: 503 year: 1926 end-page: 513 article-title: The arrangement of field experiments publication-title: J. Ministry Agric. Great Britain – volume: 21 start-page: 2437 year: 2002 end-page: 2444 article-title: A comment on replication, p‐values and evidence, S.N.Goodman, Statistics in Medicine 1992;11:875‐879 publication-title: Stat. Med. – year: 1925 – volume: 73 start-page: 1 issue: suppl. 1 year: 2019 end-page: 19 article-title: Moving to a world beyond “p<0.05” publication-title: Am. Stat. – volume: 19 start-page: 857 year: 1966 end-page: 882 article-title: The role of hypothesis testing in clinical trials publication-title: J. Chron. Dis. – volume: 169 start-page: 577 year: 2018 end-page: 578 article-title: Inappropriate statistical analysis and reporting in medical research: perverse incentives and institutional solutions publication-title: Ann. Intern. Med. – volume: 73 start-page: 1 year: 2019 end-page: 3 article-title: Why are p‐values controversial? publication-title: Am. Stat. – volume: 36 start-page: 1 year: 2014 end-page: 2 article-title: Editorial publication-title: Basic Appl. Social Psych. – volume: 11 start-page: 875 year: 1992 end-page: 879 article-title: A comment on replication, P‐values and evidence publication-title: Stat. Med. – year: 1994 – volume: 17 start-page: 8 issue: 2 year: 2020 end-page: 9 article-title: Different worlds: confirmatory versus exploratory research publication-title: Signif. (Oxf). – volume: 318 start-page: 1550 year: 2017 end-page: 1560 article-title: Effect of therapeutic hypothermia initiated after 6 hours of age on death or disability among newborns with hypoxic‐ischemic encephalopathy: a randomized clinical trial publication-title: JAMA – volume: 53 start-page: 370 year: 1763 end-page: 418 article-title: An essay towards solving a problem in the doctrine of chances publication-title: Philos. Trans. R Soc. London – volume: 70 start-page: 1 year: 2016 end-page: 2 article-title: Three inferential questions, two types of p‐value publication-title: Am. Stat. – volume: 48 start-page: 378 year: 1978 end-page: 399 article-title: The case against statistical significance testing publication-title: Harvard Educ. Rev. – volume: 14 start-page: 295 year: 2004 end-page: 327 article-title: Alphabet soup: blurring the distinctions between p’s and α’s in psychological research publication-title: Theory Psych. – volume: 33 start-page: 1 year: 1962 end-page: 67 article-title: The future of data analysis publication-title: Ann. Math. Stat. – volume: 2 year: 2005 article-title: Why most published research findings are false publication-title: PLoS Med. – volume: 564 start-page: 7 year: 2018 article-title: How sure are you of your result? Put a number on it publication-title: Nature – volume: 6 start-page: 193 year: 2001 end-page: 204 article-title: Two cheers for P‐value publication-title: J. Epidemiol. Biostat. – volume: 72 start-page: 90 year: 2016 end-page: 103 article-title: Rejection odds and rejection ratios: a proposal for statistical practice in testing hypotheses publication-title: J. Math. Psych. – volume: 73 start-page: 106 issue: suppl. 1 year: 2019 end-page: 114 article-title: Valid p‐values behave exactly as they should: some misleading criticisms of p‐values and their resolution with s‐values publication-title: Am. Stat. – year: 1997 – volume: 82 start-page: 112 year: 1987 end-page: 122 article-title: Testing a point null hypothesis: the irreconcilability of p values and evidence publication-title: J. Am. Stat. Assoc. – volume: 73 start-page: 186 issue: suppl. 1 year: 2019 end-page: 191 article-title: Three recommendations for improving the use of p‐values publication-title: Am. Stat. – volume: 73 start-page: 82 issue: suppl. 1 year: 2019 end-page: 90 article-title: Before p < 0.05 to beyond p < 0.05: using history to contextualize p‐values and significance testing publication-title: Am. Stat. – volume: 73 start-page: 69 issue: suppl. 1 year: 2019 end-page: 81 article-title: Expert knowledge elicitation: subjective but scientific publication-title: Am. Stat. – volume: 567 start-page: 305 year: 2019 end-page: 307 article-title: Retire statistical significance publication-title: Nature – volume: 96 start-page: 434 year: 2004 end-page: 442 article-title: Assessing the probability that a positive report is false: An approach for molecular epidemiology studies publication-title: J. Nat. Cancer Inst. – volume: 32 start-page: 40 year: 2014 end-page: 51 article-title: Clinical development success rates for investigational drugs publication-title: Nat. Biotech. – volume: 140 start-page: 685 year: 2017 end-page: 687 article-title: Phase 2 to phase 3 clinical trial transitions: reasons for success and failure in immunologic diseases publication-title: J. Allergy Clin. Immun. – volume: 70 start-page: 129 year: 2016 end-page: 133 article-title: The ASA's statement on p‐values: context, process, and purpose publication-title: Am. Stat. – volume: 257 start-page: 2459 year: 1987 end-page: 2463 article-title: Are all significant p values created equal? The analogy between diagnostic tests and clinical research publication-title: JAMA – volume: 381 start-page: 286 year: 2019 article-title: New guidelines for statistical reporting in the journal publication-title: N. Engl. J. Med. |
| SSID | ssj0004988 |
| Score | 2.4284468 |
| SecondaryResourceType | review_article |
| Snippet | Null hypothesis significance testing (NHST) with its benchmark P value < 0.05 has long been a stalwart of scientific reporting and such statistically... Null hypothesis significance testing (NHST) with its benchmark P value < 0.05 has long been a stalwart of scientific reporting and such statistically... |
| SourceID | proquest wiley |
| SourceType | Aggregation Database Publisher |
| StartPage | 1489 |
| Title | Détente: A Practical Understanding of P values and Bayesian Posterior Probabilities |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcpt.2004 https://www.proquest.com/docview/2430368759 |
| Volume | 109 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV09T8MwELWgMLDwjShfMhLq1KiN48QOWylUTFWGIHWL7MSWWJKqaZH6k_gd_DHukoaUDYklkaJYis7PvnfO3TtCHlwZ-CozEmITrRwujHaAxylHWy8MjISoSKuq2YSYTuVsFkabrEqshan1IX4O3HBlVPs1LnCly0ErGprOq1RIvkv2XNcTiGjGo7YmMpSy6aIGJCZohGeHbNCM_EUqt6lp5VsmR__5qmNyuGGUdFRD4ITsmPyU9KJaknrdp3FbYVX2aY9GrVj1-ozEz1-fS9TlfKQjWosXwazRt-2aF1pYGlGUBTclhUf0Sa0NFl9SbPULEC4WMBQ2hirRFkLvcxJPXuLxq7PptOCkHjhpxzU29a0rLfIpzgzLjMgCP1RemIpMS2WsaxTKu1nLNJAIj2vOhgrsHsDMehekkxe5uSRUap1pq1IeQugI3EHq1Ag_46gDb0Vgu-S-sXkCQMa_Eyo3xapMGEdvCuFT2CW9ysTJvBbcSGppZZaAcbFtJk_GUYz3q7--eE0OGOaiVKcnN6SzXKzMLdlPP5bv5eKuAg5cxUx-A1TVyPg |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NS8NAEB1qFfTit1g_V5CeGtpuNslGT7VaKtaSQ4Tewm6yC17a0rRCf5K_wz_mbNKYehM8BUIWltnZnfc2M28AbtvcdUSiOHITKSzmKWkhjhOW1LbvKo6sSIqs2YQ3HPLRyA8qcF_UwuT6ED8XbmZnZOe12eDmQrpZqobG0ywXkm3AJsOgZJgXZUFZFOlzXrRRQxTjFsqzLdosRv5ClevYNAsuvb1_TWsfdleYknRyJziAihofQj3IRamXDRKWNVZpg9RJUMpVL48gfPz6nBtlzjvSIbl8Ea4beVuveiETTQJihMFVSvAVeRBLZcoviWn2i048meFQPBqyVFsk38cQ9p7Cbt9a9VqwYhvDtNVWOnZ0m2uDqBhVNFFe4jq-sP3YSyQXSreVMAJvWlOJMMJmktGWQLu7uLb2CVTHk7E6BcKlTKQWMfORPCJ64DJWnpMwowSvPVfX4KYweoSubP5PiLGaLNKIMhNPkUD5NahnNo6mueRGlIsr0wiNaxpnsqgbhOZ59tcPr2G7H74OosHz8OUcdqjJTMnuUi6gOp8t1CVsxR_z93R2lXnRN4_Ly_Y |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ3PS8MwFMcfc4p48bc4f0aQnVa2tmmb6mluDkUZPVTYrSRtAl7asW7C_iT_Dv8xX9rVzpvgqVAaCMlL8n3pe58HcGsy1-GJZOibCG5QTwoDdRw3hLJ9VzL0igQvik144zGbTPygAfdVLkzJh_i5cNMro9iv9QKX00R1a2poPC1iIekGbFIHfS2NdaZBnRTpM1aVUUMV41bk2Z7VrVr-UpXr2rQ4XEZ7_-rWPuyuNCXpl0ZwAA2ZHkI7KKHUyw4J6xyrvEPaJKhx1csjCIdfn3NN5rwjfVLii3DeyNt61gvJFAmIBoPLnOAr8sCXUqdfEl3sF404m2FT3BqKUFt0vo8hHD2GgydjVWvBiG08pg1TqthRJlNaUVFLWon0Etfxue3HXiIYl8qUXAPelLIEygibCmr1uIkbFM6tfQLNNEvlKRAmRCIUj6mPziOqByZi6TkJ1SR45bmqBTfVoEdoyvr_BE9ltsgji-rzFB0ovwXtYoyjaYnciEq4shXh4OrCmTQaBKF-nv31w2vYDoaj6PV5_HIOO5YOTCmuUi6gOZ8t5CVsxR_z93x2VRjRN2ely3E |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=D%C3%A9tente%3A+A+Practical+Understanding+of+P+values+and+Bayesian+Posterior+Probabilities&rft.jtitle=Clinical+pharmacology+and+therapeutics&rft.au=Ruberg%2C+Stephen+J.&rft.date=2021-06-01&rft.issn=0009-9236&rft.eissn=1532-6535&rft.volume=109&rft.issue=6&rft.spage=1489&rft.epage=1498&rft_id=info:doi/10.1002%2Fcpt.2004&rft.externalDBID=10.1002%252Fcpt.2004&rft.externalDocID=CPT2004 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-9236&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-9236&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-9236&client=summon |